Navigation Links
RBC Life Sciences Reports 2011 Results
Date:3/19/2012

IRVING, Texas, March 19, 2012 /PRNewswire/ -- RBC Life Sciences, Inc. (OTCQB: RBCL), a provider of proprietary nutritional supplements, and wound care and pain management products, today reported consolidated net sales of $28.4 million for the year ended December 31, 2011, a 1% increase over 2010 consolidated net sales of $28.2 million.  For the year ended December 31, 2011, the Company reported a net loss of $71,000, or $0.00 per diluted share, compared to net earnings of $558,000, or $0.02 per diluted share, during 2010.

"During 2011, we experienced significant sales growth in our Associate network channel.  Sales increased 45% while new Associate recruiting increased 75% compared to 2010.  In May 2011, we launched a new dietary supplement product, Stem-Kine™, which, along with the expansion of our business in Southeast Asia, accounted for much of the sales growth," said RBC Life Sciences President and CEO, Clinton H. Howard. "The net loss for the year resulted mainly from investments we made in a new branch office in Taiwan, which opened October 1, 2011, and a decline in our international licensee sales."

Stem-Kine is a dietary supplement that has been shown in published human clinical studies to nutritionally enable bone marrow and other stem-cell-producing tissues, which form the natural repair and renewal system of the body, to increase their production of stem cells.  The Company distributes Stem-Kine under an exclusive license agreement that covers the U.S. and 41 other countries.

About RBC Life SciencesThrough wholly owned subsidiaries, RBC Life Sciences develops, markets and distributes high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's website at www.rbclifesciences.com.

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

For Further Information:
Steven E. Brown, Executive VP, CFO
Tel:  972-893-4000
steve.brown@rbclifesciences.comRBC Life Sciences, Inc.Summary Results of Operations(in thousands, except per share data)

(unaudited)Years Ended December 31,20112010Net sales

$

28,448$

28,157Gross profit

14,31613,686Operating profit (loss)

(71)1,044Earnings (loss) before income taxes

(211)891Provision (benefit) for income taxes

(140)333Net earnings (loss)

(71)558Earnings (loss) per share - basic

$(0.00)$0.03Earnings (loss) per share - diluted

(0.00)0.02Weighted average shares outstanding - basic

22,22921,999Weighted average shares outstanding - diluted

22,22922,436RBC Life Sciences, Inc.Condensed Consolidated Balance Sheets(in thousands)

(unaudited)December 31,20112010AssetsCash and cash equivalents

$

3,859$

4,220Inventories

6,4495,343Other current assets

1,6691,696Total current assets

11,97711,259Other assets

6,8497,085Total assets

$

18,826$

18,344Liabilities and shareholders' equityAccounts payable and accrued liabilities

$

3,237$

3,087Deferred revenue

2,9902,490Other current liabilities

182168Total current liabilities

6,4095,745Other liabilities

2,5542,723Shareholders' equity

9,8639,876Total liabilities and shareholders' equity

$

18,826$

18,344
'/>"/>

SOURCE RBC Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... ... December 02, 2019 , ... Strong public health departments ... learn, and play. Striving to fulfill their crucial mission, more and more health ... by the Public Health Accreditation Board (PHAB). Today, PHAB announced it has awarded ...
(Date:11/30/2019)... Fla. (PRWEB) , ... November 29, 2019 , ... ACC ... This long awaited expansion was due to Amazon’s incredibly large purchase of ... had been delayed by Mercedes, they’ve recently received word on vehicle availability and are ...
(Date:11/27/2019)... (PRWEB) , ... November 27, 2019 , ... Chris Draft ... him for the news he and girlfriend, Keasha, received when Keasha, a never-smoker, was ... to fight back, and 8 years ago today, standing hand-in-hand, they launched Team Draft, ...
Breaking Medicine Technology:
(Date:11/30/2019)... ROSA, Calif. (PRWEB) , ... November 29, 2019 , ... ... of the year across their family of brands—Gorilla Grow Tent, Kind LED Grow Lights, ... save 40% on the Original 5’x5’ Gorilla Grow Tent . The best-selling grow ...
(Date:11/27/2019)... (PRWEB) , ... November 27, 2019 , ... AltMed ... (source: OMMU), has announced the grand opening of its newest MÜV™ Medical ... Florida Avenue in Lakeland. , AltMed’s eleventh MÜV Dispensary in Florida, is located on ...
(Date:11/23/2019)... ... ... HolistaPet, a leading CBD manufacturer for pets, today announced a new line ... CBD Pellets for Horses . The line of horse products contains all-natural, plant-based ... , “We are truly excited to bring the amazing benefits of our CBD products ...
(Date:11/22/2019)... ... November 22, 2019 , ... Nextremity Solutions, Inc., a strategic ... Capital of the World,” Warsaw, Ind., recently completed the first several cases using ... The InCore Lapidus System is a three-part construct intended for internal fixation for ...
(Date:11/22/2019)... ... , ... Benchmark Senior Living , a human connection company and leading ... named one of the Top Places to Work for the 12th straight year in ... to have made the list every year it has been published and is the ...
Breaking Medicine News(10 mins):